J Thorac Oncol
Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.
Related Questions
The ALTA and ALEX trials showed better PFS with brigatinib v. crizotinib and alectinib v. crizotinib. How do you choose your first...
New answer by Medical Oncologist at Georgetown University Hospital (May 25, 2021)
There are several right answers here. Clearly, we favor TKI therapy over chemotherapy (and ALK+ NSCLC is not an immunotherapy-responsive tumor). Crizotinib was the first but C...